TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have a diagnosis of rheumatoid arthritis based on the American College of Rheumatology Association~* The subject has active disease at both Screening and Baseline, as defined:~  * ≥4 joints tender or painful on motion, AND~ * ≥4 joints swollen;~* The subject must have at least one knee, one elbow, one wrist or two metacarpophalangeal joints with active synovitis suitable for biopsy by the shaver technique~Exclusion Criteria:~* No arthroscopy should have been performed in the past 3 months in the same joint that is to be biopsied in this study.~* No intra-articular steroids should have been injected in the joint to be biopsied in this study in the previous 3 months.~* Subjects with evidence of hematopoietic disorders or evidence of hemoglobin levels \< 9.0 gm/dL or hematocrit \< 30 % at screening visit or within the 3 months prior to baseline synovial biopsy.~* An absolute white blood cell (WBC) count of \< 3.0 x 109/L (\<3000/mm3) or absolute neutrophil count of \<1.2 X 109/L (\<1200/mm3) at screening visit or within the 3 months prior to baseline synovial biopsy.~* Thrombocytopenia, as defined by a platelet count \<100 x 109/L (\< 100,000/mm3) at screening visit or within the 3 months prior to baseline synovial biopsy.~* Estimated GFR less than 40 ml/min based on Cockcroft Gault calculation .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP-690,550 + methotrexate (Type: EXPERIMENTAL): None
- Placebo + methotrexate (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages between 18 and 70;~2. Weighs between 40 \~ 100 kg, and BMI ≥ 18 kg/m2;~3. Must have a clinical diagnosis of CAP~4. Chest X-ray shows new or persist/progressive infiltrates~5. If female, non-lactating and at no risk or pregnancy (post-menopausal or must use adequate birth control)~6. The patient is able to take the drug orally.~Exclusion Criteria:~1. Patients with CAP that, in the investigator's judgment, is severe enough to require hospitalization for intravenous antibiotic therapy and/or supplemental oxygen therapy with ICU support~2. Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary tuberculosis or infection with other mycobacteria or fungi, known bronchial obstruction, a history of post-obstructive pneumonia, other confounding respiratory diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess, empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory infection (chronic obstructive pulmonary disease \[COPD\] is not exclusionary)~3. Clinically significant conduction or other abnormality on 12-lead ECG, or QTc interval~4. Potassium is \< 3.5 mmol/L~5. Any known disease that seriously affect the immune system~6. Active hepatitis or decompensated cirrhosis;~7. Have used quinolones or fluoroquinolones within 14 days before enrollment~8. Patients who are being or will be on a long-term medication of steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nemonoxacin 500 mg (Type: EXPERIMENTAL): None
- Levofloxacin 500 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of SYN-010 on Subjects With IBS-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have IBS-C and have a positive breath CH4 test result (\> 10 ppm) at Screening.~* Subject must meet the modified Rome III criteria for IBS-C.~* Subject must have an average abdominal pain intensity score of ≥ 3 (scale 0-10) reported at Screening and Baseline.~* Subject must have an average of fewer than 3 complete spontaneous bowel movement (CSBMs) per week.~* Subject must agree to refrain from making any lifestyle changes that may affect IBS-C symptoms from the time of Screening to the end of the study.~Exclusion Criteria:~* Subject has taken IBS treatments (prescription or over-the-counter), proton pump inhibitors, laxatives, antibiotics.~* Subject currently has any structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility, or any unexplained and clinically significant symptoms such as lower GI bleeding, rectal bleeding, heme-positive stool, iron-deficiency anemia, weight loss, or systemic signs of infection.~* Subject has been diagnosed with or has a family history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or any other form of familial colorectal cancer.~* Subject reports loose (mushy) or watery stools (Bristol Stool Form Scale \[BSFS\] score of 6 or 7).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: ACTIVE_COMPARATOR): 21 mg SYN-010
- High Dose (Type: ACTIVE_COMPARATOR): 42 mg SYN-010
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patients will be screened according to a modified TRUST1 Transfusion Score. This score attributes 1 point to each of the following conditions:~  * Hb level \< 13.5 g/dL~ * Weight \< 77 kg~ * Female sex~ * Age \> 65 years~ * Non elective surgery~ * Serum creatinine \> 1.36 mg/dL~ * Redo operation~ * Non isolated surgery~ * Factors are hemodilution-related factors, and will not be included. Non isolated surgery is mandatory for inclusion. Patients will be included in presence of at least 1 within the remaining 4 risk factors:~ * Age \> 65 years~ * Non elective surgery~ * Serum creatinine \> 1.36 mg/dL '8Redo operation INCLUSION CRITERIA (patients randomized)~    1. Combined cardiac operation with expected CPB duration \> 90 minutes~   2. At least one additional risk factor within the following: Age \> 65 years; Non elective surgery; Serum creatinine \> 1.36 mg/dL; Redo operation~Exclusion Criteria:~1. Age \< 18 years~2. Patients under thienopyridines~3. Known coagulopathy~4. Known autoimmune disorders~5. Participation in another RCT~6. Pregnancy~7. Emergency operation~8. Baseline HCT \< 35%~9. Baseline Antithrombin \< 80%~10. BSA \< 1.7 m2~WITHDRAWAL CRITERION:~1. Lowest HCT on CPB \< 23%~2. Transfusions during CPB~   * Patients randomized and not withdrawn will be DOSED with the investigational drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saline solution (Type: PLACEBO_COMPARATOR): None
- Fibrinogen (Type: ACTIVE_COMPARATOR): None
- Prothrombin complex (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benzydamine Hydrochloride Gargle in Reducing Propofol for ERCP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* undergoing ERCP~* ASA I-III~* BMI 18-30 kg/m2~Exclusion Criteria:~* allergic to propofol~* contraindicated to propofol~* had throat wound or laceration~* received analgesics or steroid in 24 hours priorly~* unstable during sedation~* procedure longer than 90 minutes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Benzydamine Hydrochloride Group (Type: ACTIVE_COMPARATOR): Subjects who were allocated in benzydamine group would gargle with 15 of ml benzydamine hydrochloride 0.15% before sedation started.
- Control Group (Type: PLACEBO_COMPARATOR): Subjects who were allocated in control group would gargle with 15 ml of water before sedation started.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Evaluation of Intranasal Nalmefene

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 to 55 years inclusive~* BMI ranging from 18 to 30 kg/m2, inclusive~* Adequate venous access~* Subjects must be non-smokers~Exclusion Criteria:~* History of clinically significant disease~* Significant trauma injury, major surgery, open biopsy within 30 days prior to screening~* Following an abnormal diet 4 weeks prior to screening~* Use of over the counter medications, dietary supplements, herbal products, vitamins or opioid analgesics 14 days before intervention~* Use of enzyme altering drugs 30 days before intervention~* Use of nasal products 28 days before intervention and throughout the study~* Previous or current opioid, alcohol, or other drug dependence~* Donated or received blood 30 days before intervention~* Women who are pregnant or breastfeeding at screening~* Women of childbearing potential unless surgically sterile or use effective contraception~* Current or recent upper respiratory tract infection~* Allergic to nalmefene

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Intranasal Nalmefene (Type: EXPERIMENTAL): Nalmefene hydrochloride nasal spray, 3mg, 1 spray
- Intramuscular Nalmefene (Type: ACTIVE_COMPARATOR): Nalmefene injection, 1mg, 1 injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ability of Pupillometry to Reduce Sufentanil Consumption in Planned Cardiac Surgery: Randomized, Controlled, Single-center Clinical Superiority Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Person who has given written consent~* Adult patient~* Patient undergoing coronary artery bypass surgery with CEC, with or without valve surgery, by sternotomy.~* ASA \<4.~Exclusion Criteria:~* Person not affiliated to the national health insurance system~* Person subject to legal protection (curatorship, guardianship)~* Person who has been deemed mentally incompetent~* Pregnant, parturient or breastfeeding woman~* Adult unable or unwilling to provide consent~* Patient with preoperative cognitive dysfunction (MMS \<13) (APPENDIX 6),~* Patient with morphine intolerance,~* Patient on long-term opioid treatment,~* Emergency surgery,~* Eye disease, corneal injury, or wearing contact lenses, a neurological disease that can influence the pupillary reflex,~* Refusal to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard group (Type: OTHER): None
- Pupillometry group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female of non-child bearing potential; 18 to 55 years old; are non-smokers and have not used nicotine products within 3 months prior to screening.~* Male or female, 18 to 60 years old, with sickle cell disease (hemoglobin SS, HbS/β0thalassemia, HbS/β+thalassemia, or HbSC) not requiring chronic blood transfusion therapy; without hospitalization in 30 days before screening or receiving blood transfusion within 30 days before screening; subjects are allowed concomitant use of hydroxyurea if the dose has been stable for the 3 months prior to screening.~Exclusion Criteria:~* Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders.~* Subjects who consume more than 14 (female subjects) or 21 (male subjects) units of alcohol a week.~* Subjects who have used any investigational product in any clinical trial within 30 days of screening~* Subjects with sickle cell disease who smoke \>10 cigarettes per day; have hemoglobin level \<6 g/dL or \>10.4 g/dL (\> ULN (appropriately corrected for gender) for Cohort 15) at screening; have aspartate aminotransferase (AST) \>4x upper limit of normal or alanine aminotransferase (ALT), or alkaline phosphatase (ALK) \>3x upper limit of normal reference range (ULN) at screening; have moderate or severe renal dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- GBT440 (Type: EXPERIMENTAL): Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Stress-reducing Aromatherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* in good physical and cognitive health~* reporting moderate level of stress~* able to perceive aromas~* able to understand and follow study instructions~Exclusion Criteria:~* taking medications affecting central nervous system (CNS) function or physiologic measures (e.g. steroids or neuroleptics)~* reporting smell sensitivities or allergies~* smoking presently or in the past less than one year prior to enrollment

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- stress reducing aroma (Type: EXPERIMENTAL): aroma with reported stress reducing effects
- Placebo aroma 1 (Type: PLACEBO_COMPARATOR): None
- Placebo aroma 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV~* The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment~* If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception~Exclusion Criteria:~* The patient has used an investigational drug within the past 30 days~* The patient has participated in a previous study of this compound

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone (Type: EXPERIMENTAL): 80 mg AM dosing once daily
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men with characteristics of metabolic syndrome~   1. Waist circumference greater than 40 in (102 cm)~  2. Plasma TG greater than 150 mg/dL~  3. HDL cholesterol less than 40 mg/dL~  4. Blood pressure greater than or equal to 130/85 mmHg~  5. Fasting plasma glucose greater than 100 mg/dL but less than 126 mg/dL~  6. Fasting insulin great than 10 microunits/mL~2. 35-60 years of age~3. Overweight/obese subjects with BMI 27.1 - 35.0 kg/m2~4. Family history of cardiovascular disease or diabetes~5. Habitual diets containing ≥ 5.0% of energy from added sugars~6. Creatinine clearance of ≥80 mL/min~Exclusion Criteria:~1. Diagnosed cardiovascular disease (unstable angina, New York Heart Association angina \> Grade 2), abnormal thyroid function or liver/kidney disease, renal dysfunction (defined by a glomerular filtration rate \<80 mL/min)~2. Chronic skin disorder or treatment for acne~3. History of clinically significant dry eye or eye diseases such as glaucoma~4. Diabetes defined as fasting glucose ≥ 125 mg/dL or HbA1c ≥ 6.5%~5. Habitual diets with low content of added sugars (\<5% of total energy)~6. Any tobacco use~7. Elevated liver enzymes ≥ 3x normal (regional norms Alanine transaminase \<42 U/L, aspartate aminotransferase \<40 U/L, and gamma-glutamyl transferase 8-61 U/L)~8. Contraindications of MRI~9. Alcohol intake weekly greater than 56 g/week (4 standard drinks/wk).~10. Major surgery or donation of blood of \>500 mL within the past 8 wks.~11. Patients with uncontrolled hypertension, i.e. ≥160/95 mmHg.~12. Patients with known cardiac abnormalities.

- Gender: MALE
- Minimum Age: 35 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 3-V Bioscience-2640 (Type: EXPERIMENTAL): Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Subjects must have a diagnosis of Pulmonary Arterial Hypertension (PAH) in clinical classification of Pulmonary Hypertension Group1~* The mean right heart catheterization parameters measured from 6 months prior to the administration of the investigational drug must meet the criteria below:~* Mean pulmonary arterial pressure (mPAP) of \>25 mmHg~* Pulmonary vascular resistance (PVR) of \>3 mmHg/L/min~* Mean pulmonary capillary wedge pressure or left ventricular end diastolic pressure of \<15 mmHg (if measurable)~* The measured six minutes walk distance (6MWD) at screening visit is in the range of =\>150m and \<=450m

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1325760A (Type: EXPERIMENTAL): Single arm safety and efficacy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete